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Background: Despite the high mortality in patients with pneumonia admitted to an ICU, data on risk factors for
death remain limited.
Methods: In this secondary analysis of PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial), we
focused on the patients admitted to ICU with a primary diagnosis of pneumonia. The primary outcome for this
study was 90-day hospital mortality and the secondary outcome was 90-day ICU mortality. Cox regression model
was conducted to examine the relationship between baseline and time-dependent variables and hospital and ICU
mortality.
Results: Six hundred sixty seven patients admitted with pneumonia (43.8 % females) were included in our analysis,
with a mean age of 60.7 years and mean APACHE II score of 21.3. During follow-up, 111 patients (16.6 %) died in
ICU and in total, 149 (22.3 %) died in hospital. Multivariable analysis demonstrated significant independent risk
factors for hospital mortality including male sex (hazard ratio (HR) = 1.5, 95 % confidence interval (CI): 1.1 - 2.2,
p-value = 0.021), higher APACHE II score (HR = 1.2, 95 % CI: 1.1 - 1.4, p-value < 0.001 for per-5 point increase),
chronic heart failure (HR = 2.9, 95 % CI: 1.6 - 5.4, p-value = 0.001), and dialysis (time-dependent effect: HR = 2.7,
95 % CI: 1.3 - 5.7, p-value = 0.008). Higher APACHE II score (HR = 1.2, 95 % CI: 1.1 - 1.4, p-value = 0.002 for per-5
point increase) and chronic heart failure (HR = 2.6, 95 % CI: 1.3 – 5.0, p-value = 0.004) were significantly related to
risk of death in the ICU.
Conclusion: In this study using data from a multicenter thromboprophylaxis trial, we found that male sex, higher
APACHE II score on admission, chronic heart failure, and dialysis were independently associated with risk of
hospital mortality in patients admitted to ICU with pneumonia. While high illness severity score, presence of a
serious comorbidity (heart failure) and need for an advanced life support (dialysis) are not unexpected risk factors
of mortality, male sex might necessitate further exploration. More studies are warranted to clarify the effect of
these risk factors on survival in critically ill patients admitted to ICU with pneumonia.
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Pneumonia is the leading cause of death from infectious
diseases globally [1]. Despite advances in antibiotics and
vaccines, as well as publication of guidelines for the
management of patients with hospital-acquired and
community-acquired pneumonia [2–4], the mortality
rate for patients admitted to intensive care unit (ICU)
with pneumonia remains substantial, ranging from ap-
proximately 15 to 50 % [5–8].
Many studies have focused on prevention of and risk
factors for pneumonia among patients admitted to the
hospital [9, 10] or ICU [6, 11]. Previous studies have
identified advanced age, renal failure, septic shock and
acute respiratory distress syndrome as significant risk
factors for pneumonia [12–15]. However, among patients
admitted to ICU due to pneumonia, data on risk factors
for death remain limited. Furthermore, the effects of some
proposed risk factors such as gender [12, 16, 17] and
the use of antiplatelet agents [18–21] on all-cause or
pneumonia-related mortality in this population have
been inconsistent. Moreover, most prospective studies
failed to analyze the time-dependent effect of the crit-
ical care management in patients admitted to ICU with
pneumonia [12–14], which could result in misleading
findings [22].
In this study, we evaluated the incidence of, and baseline
and time-dependent risk factors for, mortality in patients
admitted to ICU with pneumonia who participated in
an international randomized controlled trial (RCT) of
thromboprophylaxis, PROTECT (Prophylaxis for Thrombo-
embolism in Critical Care Trial).
Methods
Patients and settings
This is a secondary analysis of PROTECT focusing on
the patients admitted to ICU with a primary diagnosis of
pneumonia, including hospital-acquired and community-
acquired pneumonia. PROTECT was a multicenter RCT
conducted in 67 ICUs in Canada, Australia, Brazil, Saudi
Arabia, the United States and United Kingdom from 2006
to 2010, to investigate the efficacy of unfractionated
heparin (UFH) versus dalteparin (a low–molecular weight
heparin) for prevention of venous thromboembolism (VTE)
(ClinicalTrials.gov Identifier: NCT00182143) [23, 24].
Inclusion criteria were age ≥ 18 years, weight ≥ 45 kg
and expected ICU stay ≥ 3 days. Exclusion criteria were
an admission diagnosis of trauma, orthopedic surgery,
uncontrolled hypertension or neurosurgery, major
hemorrhage within the previous week, pregnancy, stroke,
thrombocytopenia, coagulopathy, and limitation of life-
support. If patients needed anticoagulant therapy, had a
contraindication to heparin or blood products, or were
already enrolled in a related trial, then they were also
excluded. Written informed consent was obtained frompatients or surrogates prior to enrolment. Except for the
blinded PROTECT study drug (i.e., UFH and dalteparin),
all other aspects of care and management decisions in-
cluding use of basic and advanced life support, antibiotics,
fluid resuscitation and surgical interventions were at the
discretion of the ICU team [24]. Research ethics board ap-
proval was obtained at each study center for the trial (de-
tails on the ethics approvals were presented in Additional
file 1: Table S1). The Hamilton Integrated Research Ethics
Board approved this secondary analysis and waived the
need for additional consent.
Outcome measures
Pneumonia was diagnosed if it represented the main rea-
son for admission to the ICU as recorded by Research
Coordinators who conferred with physicians [23, 24]. All
patients were followed to hospital discharge to docu-
ment vital status. The primary outcome was 90-day all-
cause hospital mortality and the secondary outcome was
90-day all-cause ICU mortality [24]. For hospital mortality,
patients who survived longer than 90 days in hospital or
were discharged from hospital were censored; for ICU
mortality, patients who survived longer than 90 days in
ICU or were discharged from the ICU were censored.
Independent variables
We collected data on both baseline characteristics and
time-dependent variables in this study. Possible risk fac-
tors for mortality at baseline included sex, body mass
index (BMI), APACHE (Acute Physiology and Chronic
Health Evaluation) II score on admission, medical (versus
surgical) admission, malignancy, end-stage renal disease,
chronic hepatic failure, chronic respiratory failure, chronic
heart failure, immunocompromised status, and personal
or family history of VTE. We recorded daily interventions
including use of inotropes or vasopressors, mechanical
ventilation, dialysis, red blood cell transfusion, central ven-
ous catheterization, acetylsalicylic acid or clopidogrel, sta-
tins, stress ulcer prophylaxis, erythropoietin-stimulating
agents, and activated protein C [23, 24].
Statistical analysis
We presented frequency and percentages for categorical
data, and mean and standard deviation (SD) or median
and interquartile range (IQR) for continuous variables.
Student’s t-test was used to compare continuous variables
between the survivors and non-survivors, while chi-square
test or Fisher’s exact test was used for categorical variables.
Survival curves for 90-day hospital mortality and ICU
mortality were graphed using the Kaplan–Meier survivor
function. Cox proportional hazards (PH) regression model
was conducted to examine the relationship between inde-
pendent variables and mortality, in which hazard ratios
(HRs) were used to quantify the associations. Schoenfeld
Li et al. Respiratory Research  (2016) 17:80 Page 3 of 9residuals were used to statistically test the PH assumption
of Cox models [25]. We assessed the fixed effect of base-
line variables including sex, BMI (per 5-point increase),
APACHE II score (per 5-point increase), medical admis-
sion, malignancy, end-stage renal disease, chronic hepatic
failure, chronic respiratory failure, chronic heart failure,
immunocompromised status, and personal or family his-
tory of VTE. We treated the daily interventions as time-
dependent covariates to investigate their time-dependent
effect on hospital mortality and ICU mortality [22].
Univariate Cox regression models were initially conducted
before choosing potentially significant risk factors with a
p-value level < 0.20 for multivariable analyses. Variables
with a two-sided p-value of < 0.05 in multivariable models
were considered to be significant risk factors for mortality.





Age (year): mean (SD) 60.7 (1
Female: n (%) 292 (4
BMI (kg/m2): mean (SD) 28.2 (7
APACHE II score: mean (SD) 21.3 (7
Medical admission: n (%) 650 (9
History of malignancy: n (%) 30 (4.5
End-stage renal disease: n (%) 10 (1.5
Chronic hepatic failure: n (%) 7 (1.05
Chronic respiratory disease: n (%) 117 (1
Chronic heart failure: n (%) 27 (4.0
Immunocompromise: n (%) 98 (14
Personal or family history of venous thromboembolism: n (%) 28 (4.2
Intervention within the first 24 h on admission: n (%)
Inotropes/vasopressors 284 (4
Mechanical ventilation 621 (9
Dialysis 21 (3.1
Red blood cell transfusion 37 (5.5
Central venous catheterization 532 (7
Acetylsalicylic acid or clopidogrel 169 (2
Statins 104 (1
Stress ulcer prophylaxis 584 (8
Erythropoietin-stimulating agents 5 (0.76
Activated protein C 7 (1.05
ICU intensive care unit, SD standard deviation, BMI body mass index, APACHE Acute
aMedian follow-up: 16 days, interquartile range: 10–29
bMedian follow-up: 15 days, interquartile range: 8–26
cMedian follow-up: 17 days, interquartile range: 10–30
dStudent’s t-test
eChi-square test
fFisher’s exact testmodel was detected using the variance inflation factor
(VIF) of ≥ 4.
We performed a sensitivity analysis using data censored
at 30 days for hospital and ICU mortality. All analyses
were performed using STATA Version 12 (Stata Corp.,
College Station, TX, USA) with a significance level of 0.05.
Results
There were 667 patients (43.8 % females) admitted to ICU
with a primary diagnosis of pneumonia and included in
this analysis. The mean age was 60.7 years (SD 16.0), BMI
28.2 (SD 7.7), and mean APACHE II score 21.3 (SD 7.5).
Most patients (97.5 %) had a medical reason for ICU
admission. The proportions of patients with baseline
comorbidities including malignancy, end-stage renal








5.95) 68.4 (13.80) 58.5 (15.85) <0.001d
3.78) 54 (36.24) 238 (45.95) 0.035e
.71) 27.7 (7.44) 28.3 (7.78) 0.36d
.53) 24.6 (7.36) 20.4 (7.32) <0.001d
7.45) 147 (98.67) 503 (97.10) 0.29e
0) 11 (7.38) 19 (3.67) 0.054e
0) 5 (3.36) 5 (0.97) 0.034f
) 1 (0.67) 6 (1.16) 0.61f
7.54) 39 (26.17) 78 (15.06) 0.002e
5) 13 (8.72) 14 (2.70) 0.001e
.69) 28 (18.79) 70 (13.51) 0.11e
0) 4 (2.68) 24 (4.63) 0.30f
2.58) 78 (52.35) 206 (39.77) 0.006e
3.10) 140 (93.96) 481 (92.86) 0.64e
5) 11 (7.38) 10 (1.93) 0.001e
5) 13 (8.72) 24 (4.63) 0.054e
9.76) 133 (89.26) 399 (77.03) 0.001e
5.34) 54 (36.24) 115 (22.20) 0.001e
5.59) 28 (18.79) 76 (14.67) 0.22e
8.35) 135 (91.84) 449 (87.35) 0.14e
) 2 (1.35) 3 (0.59) 0.35f
) 2 (1.35) 5 (0.97) 0.69f
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however, 17.5 % of patients had chronic respiratory dis-
ease and 14.7 % were immunocompromised (Table 1).
Within the first 24 h of ICU admission, most patients
received mechanical ventilation (93.1 %), central venous
catheterization (79.8 %), and stress ulcer prophylaxis
(88.4 %). There were 42.6 % of patients requiring ino-
tropes or vasopressors, 25.3 % receiving acetylsalicylic
acid or clopidogrel, and 21 patients (3.2 %) requiring
dialysis within the first 24 h of admission (Table 1).
Of the 667 patients during follow-up, 149 patients
(22.3 %) died in hospital in total. The median hospital
stay for survivors was 17 days (IQR: 10–30), and 15 days
(IQR: 8–26) for non-survivors. Figure 1 displays the
Kaplan-Meier survival curves for 90-day hospital mortal-
ity. Table 1 shows the unadjusted comparison between
hospital survivors and non-survivors. At baseline, non-
survivors were significantly older, were more likely to be
male, and had higher APACHE II scores than survivors.
More non-survivors had end-stage renal disease, chronic
respiratory disease and heart failure. Within the first 24 h,
hospital non-survivors were more likely to have received
inotropes or vasopressors, dialysis, central venous
catheterization, and acetylsalicylic acid or clopidogrel
than survivors (p-values < 0.05) (Table 1).
Table 2 presents the results from univariate and multi-
variable analyses for 90-day hospital mortality. In the
univariate analysis, higher APACHE II score, chronic
heart failure, use of inotropes or vasopressors, dialysis,
central venous catheterization, and acetylsalicylic acid or
clopidogrel were found to be significantly related to
increased risk of hospital mortality (p-values < 0.05).
The multivariable analysis demonstrated significant riskFig. 1 KM curve for 90-day Hospital mortalityfactors for hospital mortality including male (HR = 1.5,
95 % CI: 1.1 – 2.2, p-value = 0.021), higher APACHE II
score (HR = 1.2, 95 % CI: 1.1 - 1.4, p-value < 0.001 for per-
5 point increase), chronic heart failure (HR = 2.9, 95 % CI:
1.6 - 5.4, p-value = 0.001), and dialysis (time-dependent ef-
fect: HR = 2.7, 95 % CI: 1.3 - 5.7, p-value = 0.008) (Table 2).
No multicollinearity of independent variables or violation
of the PH assumption in Cox models was observed.
There were 111 deaths (16.6 %) during the ICU stay in
this study, with a median survival time of 11 days (IQR:
6–24). Survivors stayed in ICU for a median of 8.5 days
(IQR: 5–14). Fig. 2 shows the Kaplan-Meier survival
curves for 90-day ICU mortality. Table 3 displays the re-
sults from Cox model evaluating the relationship between
independent variables and 90-day ICU mortality. Male
sex, APACHE II score, chronic heart failure and dialysis
were found to be significantly associated with ICU mortal-
ity in the univariate analysis. In the multivariable analysis,
only higher APACHE II score (HR = 1.2, 95 % CI: 1.1 - 1.4,
p-value = 0.002 for per-5 point increase) and chronic heart
failure (HR = 2.6, 95 % CI: 1.3 – 5.0, p-value = 0.004) were
significantly associated with ICU mortality (Table 3).
Similar results from multivariable analyses were found
in the sensitivity analysis when the data were censored
at 30 days for hospital and ICU mortality (Table 4).
Discussion
In this multicenter trial database analyzed to assess risk
factors for mortality in critically ill patients admitted to
ICU with pneumonia, we found that 17 % of patients
died in ICU and 22 % died in the hospital. Higher APA-
CHE II score on admission to the ICU and chronic heart
failure were significantly related to risk of death in the
Table 2 Results from univariate and multivariable analyses assessing the relationship between independent variables and 90-day
hospital mortality
Independent variables Hospital mortalitya
Univariate analysis Multivariable analysisb
HR (95 % CI) P-value HR (95 % CI) P-value
Baseline variables
Male 1.37 (0.97-1.92) 0.074 1.52 (1.07-2.17) 0.021
APACHE II scorec 1.25 (1.13-1.38) <0.001 1.23 (1.10-1.37) <0.001
History of malignancy 1.84 (0.99-3.41) 0.053 1.61 (0.82-3.15) 0.16
End-stage renal disease 1.96 (0.79-4.88) 0.15 1.12 (0.38-3.25) 0.84
Chronic respiratory disease 1.40 (0.97-2.03) 0.073 1.36 (0.91-2.02) 0.14
Chronic heart failure 2.71 (1.53-4.79) 0.001 2.90 (1.57-5.37) 0.001
History of venous thromboembolism 0.50 (0.19-1.37) 0.18 0.64 (0.23-1.75) 0.38
Immunocompromise 1.40 (0.93-2.12) 0.12 1.33 (0.84-2.12) 0.23
BMIc 0.99 (0.89-1.10) 0.82 -d -d
Medical admission 2.45 (0.61-9.90) 0.22 -d -d
Chronic hepatic failure 0.65 (0.091-4.64) 0.67 -d -d
Daily intervention variables
Inotropes/vasopressors 1.59 (1.15-2.19) 0.005 1.24 (0.88-1.75 0.22
Dialysis 2.84 (1.52-5.30) 0.001 2.71 (1.30-5.65) 0.008
Red blood cell transfusion 1.64 (0.93-2.91) 0.090 1.22 (0.67-2.21) 0.51
Central venous catheterization 1.75 (1.04-2.94) 0.037 1.67 (0.99-2.80) 0.056
Acetylsalicylic acid or clopidogrel 1.44 (1.03-2.01) 0.034 1.28 (0.90-1.81) 0.17
Mechanical ventilation 1.34 (0.68-2.63) 0.40 -d -d
Statins 1.27 (0.84-1.92) 0.26 -d -d
Stress ulcer prophylaxis 1.43 (0.79-2.59) 0.23 -d -d
Erythropoietin-stimulating agents 2.29 (0.57-9.30) 0.25 -d -d
Activated protein C 1.64 (0.41-6.67) 0.49 -d -d
HR hazard ratio, CI confidence interval, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation
aThere were 143 deaths for 90-day hospital mortality, bNo multicollinearity detected, cResults for 5-point increase, dNot included in the multivariable analysis
Fig. 2 KM curve for 90-day ICU mortality
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Table 3 Results from univariate and multivariable analyses investigating the relationship between independent variables and 90-day
ICU mortality
Independent variables ICU mortalitya
Univariate analysis Multivariable analysisb
HR (95 % CI) P-value HR (95 % CI) P-value
Baseline variables
Male 1.52 (1.01-2.22) 0.042 1.41 (0.95-2.08) 0.096
APACHE II scorec 1.20 (1.07-1.35) 0.002 1.22 (1.07-1.37) 0.002
Chronic respiratory disease 1.47 (0.97-2.23) 0.071 1.27 (0.81-1.97) 0.30
Chronic heart failure 2.48 (1.33-4.64) 0.004 2.58 (1.34-4.97) 0.004
History of venous thromboembolism 0.28 (0.068-1.16) 0.078 0.46 (0.11-1.91) 0.29
Immunocompromise 1.45 (0.91-2.33) 0.11 1.54 (0.94-2.52) 0.084
BMIc 0.97 (0.85-1.10) 0.61 -d -d
History of malignancy 1.29 (0.57-2.94) 0.54 -d -d
Medical admission 1.24 (0.31-5.04) 0.76 -d -d
End-stage renal disease 1.49 (0.50-4.40) 0.47 -d -d
Chronic hepatic failure 1.21 (0.17-8.67) 0.85 -d -d
Daily intervention variables
Inotropes/vasopressors 1.35 (0.92-1.98) 0.12 1.29 (0.88-1.92) 0.19
Dialysis 2.06 (1.04-4.09) 0.039 1.64 (0.77-3.52) 0.20
Red blood cell transfusion 1.60 (0.83-3.09) 0.16 1.30 (0.63-2.70) 0.48
Central venous catheterization 1.75 (0.93-3.27) 0.081 1.63 (0.92-2.87) 0.090
Erythropoietin-stimulating agents 2.66 (0.65-10.85) 0.17 1.15 (0.23-5.79) 0.86
Mechanical ventilation 1.05 (0.46-2.40) 0.91 -d -d
Acetylsalicylic acid or clopidogrel 1.22 (0.82-1.81) 0.32 -d -d
Statins 0.93 (0.56-1.55) 0.78 -d -d
Stress ulcer prophylaxis 1.33 (0.64-2.74) 0.44 -d -d
Activated protein C 0.86 (0.21-3.50) 0.84 -d -d
HR hazard ratio, CI confidence interval, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation
aThere were 108 deaths for 90-day ICU mortality
bNo multicollinearity detected
cResults for 5-point increase
dNot included in the multivariable analysis
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failure, and dialysis were independently associated with
risk of death in hospital.
The substantial mortality rate of patients admitted to
ICU with pneumonia has been described in prior studies,
despite heterogeneous healthcare systems, study designs,
treatments, and guideline adherence [8, 26–28]. A large
multicenter international cohort study of 1166 patients
admitted to ICU with pneumonia in Europe reported an
ICU mortality of 19 % and a hospital mortality of 24 % [8],
which is comparable to our study. In our study, males
were more likely to die in hospital than females (HR = 1.5).
The impact of gender on mortality in critically ill patients
with pneumonia remains controversial. Some studies re-
ported a lower risk of death in females [6, 29, 30], whereas
others demonstrated a higher mortality rate for women
[16, 31]. It has been postulated that gender differencesin mortality may relate to sex steroids [16, 32]. Female
sex hormones appear to be immune-stimulatory, while
male sex hormones appear to be immunosuppressive,
potentially partially explaining the lower risk of mortal-
ity in critically ill female patients [30, 33]. However, the
result should be interpreted with caution because our
analyses could not be adjusted for other potential con-
founding factors including smoking and alcohol abuse
that might influence the effect of sex on mortality.
Higher APACHE II score on admission to the ICU
and chronic heart failure have previously been found to
be independently associated with increased risk of death
[7, 8, 34, 35]. A large population-based cohort study in
Denmark reported a 30-day mortality risk ratio of 1.4 in
heart-failure patients hospitalized for pneumonia com-
pared to patients without pneumonia [35], which was
consistent with our findings that baseline chronic heart
Table 4 Sensitivity analysis results from multivariable analyses evaluating the relationship between independent variables and
30-day hospital and ICU mortality
Independent variables Hospital mortalitya ICU mortalityb
HR (95 % CI) P-value HR (95 % CI) P-value
Baseline variables
Male 1.39 (0.96-1.96) 0.090 1.30 (0.85-2.04) 0.22
APACHE II scorec 1.29 (1.14-1.47) <0.001 1.20 (1.06-1.37) 0.004
History of malignancy 1.46 (0.70-3.03) 0.31 -d -d
End-stage renal disease 1.13 (0.38-3.39) 0.82 -d -d
Chronic respiratory disease 1.49 (0.98-2.27) 0.063 1.45 (0.92-2.28) 0.11
Chronic heart failure 2.25 (1.16-4.34) 0.017 2.57 (1.32-5.02) 0.006
History of venous thromboembolism 0.76 (0.28-2.09) 0.59 0.52 (0.13-2.12) 0.36
Immunocompromise 1.48 (0.91-2.41) 0.12 1.43 (0.85-2.39) 0.17
Daily intervention variables
Inotropes/vasopressors 1.21 (0.84-1.75) 0.31 1.07 (0.71-1.62) 0.75
Dialysis 2.29 (1.03-5.11) 0.042 1.33 (0.59-2.98) 0.49
Red blood cell transfusion 1.20 (0.62-2.30) 0.59 1.38 (0.67-2.84) 0.39
Central venous catheterization 1.50 (0.86-2.63) 0.15 1.12 (0.62-2.01) 0.72
Acetylsalicylic acid or clopidogrel 1.36 (0.93-2.00) 0.11 -d -d
Erythropoietin-stimulating agents -e -e 1.39 c0.32-6.04) 0.66
HR hazard ratio, CI confidence interval, BMI body mass index, APACHE Acute Physiology and Chronic Health Evaluation
aThere were 122 deaths for 30-day hospital mortality; No multicollinearity detected
bThere were 97 deaths for 30-day hospital mortality; No multicollinearity detected
cResults for 5-point increase
dNot included in the multivariable analysis for ICU mortality
eNot included in the multivariable analysis for hospital mortality
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(Table 2, Table 3). Similarly, the need for dialysis was as-
sociated with an increased risk of death in patients with
pneumonia, as has been shown for critically ill patients
in general [7, 13, 36].
In contrast to other previous reports [8, 34, 37], we
found no significant relationship between mechanical
ventilation and risk of death in this study (Tables 2 and 3).
This may be because almost all of the patients received
mechanical ventilation (93 %, Table 1). It is unlikely that a
variable will be a significant risk factor for an outcome in
regression analysis if the variable characterizes a very high
proportion in the population [38]. Use of antiplatelet
agents or statins was not related with hospital or ICU
mortality in this study. Prior studies have shown that anti-
platelets and statins could modulate inflammatory reac-
tions to attentuate the severity of pneumonia and the
development of organ failure in critically ill patients,
which was therefore associated with improved outcomes
[19–21]. Some observational studies reported a significant
inverse relationship between mortality and antiplatelet
agents [20, 21, 39] or statins [19, 40]; however, our find-
ings agree with the results from other randomized trials
[18, 41, 42] that did not support the beneficial effect on
short-term all-cause or pneumonia-related mortality.
More evidence is needed to further clarify the possiblemechanisms of action and possible clinical effects of anti-
platelet agents and statins on survival during critical illness
in ICU patients with pneumonia.
Strengths of this study include the multicenter design
and heterogeneous group of patients from six countries.
Associations between risk of mortality in patients admitted
to ICU with pneumonia and gender and use of antiplatelet
agents were evaluated, given the inconsistent findings from
other studies. In this study we focused on patients admitted
to ICU with pneumonia, because previous studies typically
investigated how to prevent pneumonia after ICU ad-
mission, or how to improve survival for all the hospital-
ized patients with pneumonia (rather than those critically
ill patients requiring ICU admission). We used rigorous
analytic approaches to assess the relationship between
baseline and time-dependent risk factors and mortality to
avoid potential confounding and misleading findings. Fur-
thermore, our study yielded similar results to the 90-day
mortality in the 30-day mortality sensitivity analysis, which
may provide some value to the existing literature because
studies of ICU patients with infection have typically fo-
cused on the shorter term follow-up [11, 18, 41, 42]. There
are several limitations of our study. First, because the diag-
nosis of pneumonia was made by physicians’ in practice,
we lack specific diagnostic criteria used in each case (e.g.,
type of chest x-ray infiltrate). We also acknowledge that
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to ICU [43, 44]; however, disincentivized reporting of
pneumonia as a quality metric in many settings indi-
cates that pneumonia may also be under-diagnosed and
under-reported as well. Furthermore, although both
hospital-acquired pneumonia and community-acquired
pneumonia were included in this analysis, we could not
distinguish them, as the diagnosis was not centrally ad-
judicated. Therefore we could not evaluate whether
their risk factors for mortality differed. Similarly due to
no central adjudication of infection, some patients may
have had underlying pneumonia but received a primary
diagnosis of septic shock or acute respiratory distress
syndrome on ICU admission, and were not categorized
as having pneumonia in this study. Moreover, no data on
microbiology, degree of hypoxia, respiratory mechanics,
inflammatory biomarkers, or antimicrobials were docu-
mented in this thromboprophylaxis trial; treatment was
at the physicians’ discretion, replicating practice [24].
Because there is no well-validated classification for cause-
specific mortality for critically ill patients, we used all-
cause mortality, as per the trial database [23]. Using
data from a randomized thromboprophylaxis trial with
topic-specific eligibility criteria [23, 24] could limit the
generalizability of these findings. The number of deaths
(143 for 90-day hospital mortality, Table 2; 108 for 90-day
ICU morality, Table 3) resulted in imprecise estimates of
the strength of the risk factors in our multivariable analyses,
rendering the regression analysis potentially underpowered
to assess these or other risk factors.
Conclusion
In summary, in this study using data from a multicenter
thromboprophylaxis trial, we found that male sex, higher
APACHE II score on admission, chronic heart failure,
and dialysis were independently associated with risk of
hospital mortality in patients admitted to ICU with
pneumonia. None of these are modifiable risk factors.
Findings from this study may help to inform clinicians
about prognostic factors for patients with pneumonia
and identify higher-risk patients who may benefit from
closer monitoring. While high illness severity score, pres-
ence of a serious comorbidity (heart failure) and need for
an advanced life support (dialysis) are not unexpected risk
factors of mortality, male sex might necessitate further ex-
ploration. More studies are warranted to clarify the effect
of these risk factors on survival in critically ill patients ad-
mitted to ICU with pneumonia.Additional file
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